Axitinib showing promise for rcc
November 1, 2007
A new drug from Pfizer has demonstrated positive results in Phase II trials in the U.S.
Phase III trials are open in the U.S. and some sites in Canada. Axinitib is being studied as a 2nd line treatment for mrcc (clear cell) versus sorafenib (Nexavar)
For more information about Axinitib:
Clinical trial information is available at www.clinicaltrials.gov (search for Axitinib).